fashion -WSS

fashion

author：leisure time 2025-09-14 18:33:04 - browse：86581

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Cassava reveals details — and problems — with Alzheimer's study

entertainment

WSS

The new shift in health care is toward less care

More doctors should go into startup world

Maker of FluMist seeks to allow at

Free speech concerns arise in wake of journal editor Eisen's firing

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Biden's order seeks to regulate AI risk without stifling innovation

Wikipedia

fashion

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Medicare will require more price transparency from hospitals

Activists slam private health insurers over coverage restrictions

Eli Lilly to pay $200M for Beam’s stake in gene

Cancer drug shortages should be causing more outrage

Maker of FluMist seeks to allow at

Activists slam private health insurers over coverage restrictions

Readout Newsletter: What happened with Sarepta's Duchenne data

Heart attack and stroke risk calculators need revising

Free speech concerns arise in wake of journal editor Eisen's firing

explore

Study: New antibiotic targets gonorrhea as well as last existing drug

Medicare solvency divides Republicans at the presidential debate

White House calls on federal agencies to crack down on AI abuses

FDA has safety concerns on CRISPR

Abortion clinic in Cancun will cater to Americans

MoonLake credibility takes another hit with mid

entertainment

entertainment

Wikipedia

knowledge